Intech Biopharm

Intech Biopharm Earnings Yield

The Earnings Yield of Intech Biopharm (6461.TWO) as of Oct 23, 2026 is -10.87 %. In the previous year, Earnings Yield was -10.28 % — a change of 5.66% (lower).

Earnings Yield

-10.87 %

YoY

5.66%

Last updated:

Earnings Yield of Intech Biopharm is 2025 -10.87 % . Earnings Yield of Intech Biopharm was 2024 -10.28 % . It decreases by 5.66% lower compared to the previous year.

The Intech Biopharm Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
-6.20 TWD
Jan 1, 2019
-8.70 TWD
Jan 1, 2020
-6.99 TWD
Jan 1, 2021
-8.43 TWD
Jan 1, 2022
-9.16 TWD
Jan 1, 2023
-9.44 TWD
Jan 1, 2024
-10.28 TWD
Jan 1, 2025
-10.87 TWD
The Intech Biopharm Earnings Yield history
YEAREarnings YieldYoY
-10.87 %+5.66%
-10.28 %+8.94%
-9.44 %+3.08%
-9.16 %+8.66%
-8.43 %+20.52%
-6.99 %-19.60%
-8.70 %+40.23%
-6.20 %-7.20%
-6.68 %+90.73%
-3.50 %+7.91%
-3.25 %+47.91%
-2.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intech Biopharm Stock analysis

What does Intech Biopharm do? Intech Biopharm Ltd is a pharmaceutical company based in Taipei City, Taiwan. The company went public on July 15, 2014, with the ticker symbol 6461.TWO and ISIN TW0006461007. It operates within the Health Care sector, specifically in the Pharmaceuticals industry. Intech Biopharm focuses on developing drugs for obstructive airway diseases, including bronchial asthma and chronic obstructive pulmonary disease. The company's primary products are respiratory drugs, notably the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. These products are distributed both domestically within Taiwan and internationally. The company maintains a website at http://www.intechbiopharm.com/ for further information. Intech Biopharm Ltd is engaged in the research, development, and distribution of pharmaceutical products targeting respiratory conditions, with a focus on innovative inhaler technologies. The firm's operations are centered on addressing unmet medical needs in respiratory care through its specialized drug formulations. Intech Biopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intech Biopharm stock

Earnings Yield of Intech Biopharm is -10.87 % in 2025.

Earnings Yield of Intech Biopharm changed from -10.28 % to -10.87 %, representing a 5.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Intech Biopharm since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Intech Biopharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Intech Biopharm

All Key Metrics — Intech Biopharm